Option-To-Acquire In Medical Device Deals Rarely Gets Exercised
This article was originally published in Start Up
For a device start-up, an option to acquire presents a clear path to liquidity, but there are drawbacks. An analysis of deals in Elsevier’s Strategic Transactions suggests the importance of such options to the overall merger and acquisition ecosystem might be overblown.
You may also be interested in...
Neuromodulation Start-Ups: Abundant Funding, Slow Exits
The field of neuromodulation has produced numerous start-ups and a decent amount of fundraising activity over the past six years, but exits are scarce.
Device/Diagnostics Quarterly Deal Statistics, Q4 2013
Device companies finished 2013 strong, raising $1.2 billion in Q4, the highest quarter total of the year. CVS Caremark’s $2.1 billion buy of Apria’s infusion therapy business was the largest M&A of the year, and late-stage venture rounds dominated the $423 million total in diagnostics funding.
Hospitals, Insurers Enjoy Growing Influence As VCs
Over a decade ago, hospital companies began establishing venture capital funds to ride shotgun with institutional VCs, hoping to get a glimpse of health care’s future. Today, under health care reform, VC groups sponsored by providers and payors increasingly find themselves in the driver’s seat, looking for the start-ups that might have solutions to the industry’s biggest problem – cost.